Source-grounded facts extracted from HUMANA INC's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
HUMANA INC entered into trust expense reimbursement agreements with Horseshoe Funding Trust I, Horseshoe Funding Trust II (effective 2026-05-15).
“The Company also entered into separate trust expense reimbursement agreements with each Trust. An Issuance Right will be exercised automatically in full upon certain payment defaults under the applicable Facility Agreement or trust expense reimbursement agreement, or upon certain bankruptcy events involving the Company.”
HUMANA INC entered into Facility Agreements with Horseshoe Funding Trust I, Horseshoe Funding Trust II, The Bank of New York Mellon Trust Company, N.A., as trustee valued at up to $750,000,000 aggregate principal amount of the applicable Senior Notes (effective 2026-05-15).
“On the Closing Date, the Company also entered into separate facility agreements (each, a “Facility Agreement”) with each Trust and The Bank of New York Mellon Trust Company, N.A., as trustee for the Senior Notes (the “Trustee”). Under the Facility Agreements, each Trust granted the Company the right to require such Trust to purchase, on one or more occasions, up to $750,000,000 aggregate principal amount of the applicable Senior Notes”
HUMANA INC entered into Purchase Agreements with Goldman Sachs & Co. LLC, BofA Securities, Inc., Citigroup Global Markets Inc., Morgan Stanley & Co. LLC and Wells Fargo Securities, LLC, as representatives of the several initial purchasers valued at $750,000,000 per Trust (effective 2026-05-05).
“On May 15, 2026 (the “Closing Date”), pursuant to separate Purchase Agreements, dated May 5, 2026, among Humana Inc. (the “Company”), Goldman Sachs & Co. LLC, BofA Securities, Inc., Citigroup Global Markets Inc., Morgan Stanley & Co. LLC and Wells Fargo Securities, LLC, as representatives of the several initial purchasers, and Horseshoe Funding Trust I (the “2036 Trust”) and Horseshoe Funding Trust II (the “2055 Trust” and, together with the 2036 Trust, the “Trusts”), the 2036 Trust and the 2055 Trust each completed the issuance and sale of 750,000 Pre-Capitalized Trust Securities (the “2036 P-Caps” and the “2055 P-Caps,” respectively, and together, the “P-Caps”) for an aggregate purchase price of $750,000,000 per Trust”
HUMANA INC reported the year ending December 31, 2026 results: EPS at least $9.00. Guidance reaffirmed.
“Affirms Adjusted FY 2026 GAAP EPS guidance of 'at least $9.00'; while revising GAAP EPS guidance to 'at least $8.36' from the previous estimate of 'at least $8.89'”
HUMANA INC reported the quarter ended March 31, 2026 results: EPS $9.83.
“Reports 1Q26 earnings per share (EPS) of $9.83 on a GAAP basis, Adjusted EPS of $10.31”
HUMANA INC incurred senior notes of $1.0 billion aggregate principal amount of its 6.625% Fixed-to-Fixed Rate Junior Subordinated Notes due 2056 with The Bank of New York Mellon Trust Company, N.A., as trustee at annual rate of 6.625% to, but excluding September 15, 2031, following which such maturing September 15, 2056.
“The Subordinated Notes bear interest at an annual rate of 6.625% to, but excluding September 15, 2031, following which such rate will reset in successive five-year periods until maturity at a rate equal to Five-year U.S. Treasury Rate as of the Reset Interest Determination Date (each as defined in the First Supplemental Indenture) plus 2.891%; provided, that any such interest rate will not reset below 6.625%.”
HUMANA INC entered into First Supplemental Indenture with The Bank of New York Mellon Trust Company, N.A. (effective 2026-03-09).
“as supplemented by a first supplemental indenture, dated as of March 9, 2026, by and between the Company and the Trustee relating to the Subordinated Notes (the “First Supplemental Indenture””
HUMANA INC entered into Original Indenture with The Bank of New York Mellon Trust Company, N.A. (effective 2026-03-05).
“The Subordinated Notes were issued under an amended and restated indenture dated as of March 5, 2026, by and between the Company and The Bank of New York Mellon Trust Company, N.A., as trustee (the “Trustee”) (the “Original Indenture")”
HUMANA INC entered into Underwriting Agreement with Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC, Mizuho Securities USA LLC, Truist Securities, Inc. and Wells Fargo Securities, LLC valued at $1.0 billion (effective 2026-03-05).
“On March 5, 2026, Humana Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC, Mizuho Securities USA LLC, Truist Securities, Inc. and Wells Fargo Securities, LLC, as representatives of the several underwriters (together, the “Underwriters”), pursuant to which the Company agreed to issue and sell to the Underwriters $1.0 billion aggregate principal amount of its 6.625% Fixed-to-Fixed Rate Junior Subordinated Notes due 2056”
HUMANA INC amended revolving credit of $5.0 billion with JPMorgan Chase Bank, N.A. as Agent at Term SOFR, Daily Simple SOFR or the base rate plus a spread.
“The Revolving Credit Agreement (i) increases the amount of the commitments under the Existing 5-Year Credit Agreement from $2.642 billion to $5.0 billion”
HUMANA INC incurred senior notes of $250 million aggregate principal amount with J.P. Morgan Securities LLC and Barclays Capital Inc., as representatives of the several underwriters at 5.375% maturing April 15, 2031.
“Inc., as representatives of the several underwriters (together, the “Underwriters”), pursuant to which the Company agreed to issue and sell to the Underwriters an additional $250 million aggregate principal amount of its 5.375% Senior Notes due 2031 (the “Additional 2031 Notes”), in accordance with the terms and conditions set forth in the Underwriting Agreement.”
HUMANA INC incurred senior notes of $500 million with The Bank of New York Mellon Trust Company, N.A. at 6.000% maturing May 1, 2055.
“The Senior Notes were issued under an indenture dated as of August 5, 2003, by and between the Company and The Bank of New York Mellon Trust Company, N.A. (formerly known as The Bank of New York Trust Company, N.A.) (as successor to The Bank of New York), as trustee (the “Trustee”) (the “Original Indenture”), as supplemented by a thirtieth supplemental indenture, dated as of March 5, 2025, by and between the Company and the Trustee relating to the 2035 Senior Notes (the “Thirtieth Supplemental Indenture” and, together with the Original Indenture, the “Thirtieth Indenture”) and a thirty-first supplemental indenture, dated as of March 5, 2025, by and between the Company and the Trustee relating to the 2055 Senior Notes (the “Thirty-First Supplemental Indenture” and, together with the Original Indenture, the “Thirty-First Indenture,” and the Thirtieth Indenture and Thirty-First Indenture ar”
HUMANA INC incurred senior notes of $750 million with The Bank of New York Mellon Trust Company, N.A. at 5.550% maturing May 1, 2035.
“the Company agreed to issue and sell to the Underwriters $750 million aggregate principal amount of its 5.550% Senior Notes due 2035”
Gordon Smith was elected as director at HUMANA INC.
“Effective October 23, 2024, the Board of Directors (the “Board”) of Humana Inc. (the “Company”) expanded its number of authorized directors from eleven to twelve and elected Gordon Smith as a director of the Company.”
James A. Rechtin was elected as Director at HUMANA INC.
“Mr. Rechtin will be elected to the Company’s Board of Directors”
James A. Rechtin was appointed as President and Chief Executive Officer at HUMANA INC.
“James A. Rechtin would become President and Chief Executive Officer at that time.”
Bruce D. Broussard resigned as Director at HUMANA INC.
“The Company also expects that Mr. Broussard will resign from the Company’s Board of Directors, and Mr. Rechtin will be elected to the Company’s Board of Directors, in each case effective as of July 1, 2024.”
Bruce D. Broussard departed as Chief Executive Officer at HUMANA INC.
“Bruce D. Broussard, Chief Executive Officer, would be stepping down from that role in the latter half of 2024”
HUMANA INC reported year ending December 31, 2024 results: EPS $16.00. Guidance reaffirmed.
“Humana revised its GAAP EPS guidance for the year ending December 31, 2024 (FY 2024) to approximately $13.93 from approximately $14.87, while affirming its Adjusted EPS guidance of approximately $16.00.”
HUMANA INC reported quarter ended March 31, 2024 results: revenue $29,611, EPS $6.11.
“and segment statistics comparing 1Q24 to 1Q23 follows. 2 Humana Inc. Summary of Results ($ in millions, except per share amounts) 1Q24 (a) 1Q23 (a) CONSOLIDATED Revenues $29,611 $26,742 Revenues - Adjusted (non-GAAP) $29,332 $25,652 Pretax results $1,014 $1,614 Pretax results - Adjusted (non-GAAP) $1,191 $1,552 EPS $6.11 $9.87 EPS - Adjusted (non-GAAP)”
HUMANA INC shareholders approved Stockholder proposal on simple majority vote at the 2024-04-18 meeting.
“Proposal #6 For Against Abstained Broker Non-Votes Stockholder proposal on simple majority vote 49,977,350 47,454,113 376,486 5,572,071”
HUMANA INC shareholders approved Amendment to the Company’s Restated Certificate of Incorporation to eliminate supermajority voting requirement in connection with certain transactions at the 2024-04-18 meeting.
“Proposal #5 For Against Abstained Broker Non-Votes Amendment to the Company’s Restated Certificate of Incorporation to eliminate supermajority voting requirement in connection with certain transactions 96,562,716 1,076,542 168,691 5,572,071”
HUMANA INC shareholders approved Amendment to the Company’s Restated Certificate of Incorporation to limit the liability of certain officers of the Company as permitted by Delaware law at the 2024-04-18 meeting.
“Proposal #4 For Against Abstained Broker Non-Votes Amendment to the Company’s Restated Certificate of Incorporation to limit the liability of certain officers of the Company as permitted by Delaware law 83,361,627 14,226,255 220,067 5,572,071”
HUMANA INC shareholders approved Board proposal regarding advisory approval of the Company’s executive compensation at the 2024-04-18 meeting.
“Proposal #3 For Against Abstained Broker Non-Votes Board proposal regarding advisory approval of the Company’s executive compensation 89,131,142 8,422,934 253,873 5,572,071”
HUMANA INC shareholders approved Ratification of the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2024 at the 2024-04-18 meeting.
“Proposal #2 For Against Abstained Broker Non-Votes Ratification of the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2024 95,761,126 7,454,977 163,917 N/A”
HUMANA INC shareholders approved Election of Directors at the 2024-04-18 meeting.
“Proposal #1 : The final results of the election of directors were as follows:”
HUMANA INC incurred senior notes of $1,250 million aggregate principal amount of its 5.375% Senior Notes due 2031 and $1,000 million aggregate principal amo with Citigroup Global Markets Inc., Goldman Sachs & Co. LLC, Morgan Stanley & Co. LLC, PNC Capital Markets LLC and Wells Fargo Securities, LLC at 5.375% and 5.750% maturing April 15, 2031 and April 15, 2054.
“On March 13, 2024, the Company completed a public offering of the 2031 Senior Notes and the 2054 Senior Notes.”
HUMANA INC entered into Twenty-Ninth Supplemental Indenture with The Bank of New York Mellon Trust Company, N.A. (effective 2024-03-13).
“and a twenty-ninth supplemental indenture, dated as of March 13, 2024, by and between the Company and the Trustee relating to the 2054 Senior Notes (the “Twenty-Ninth Supplemental Indenture””
HUMANA INC entered into Twenty-Eighth Supplemental Indenture with The Bank of New York Mellon Trust Company, N.A. (effective 2024-03-13).
“The Senior Notes were issued under an indenture dated as of August 5, 2003, by and between the Company and The Bank of New York Mellon Trust Company, N.A. (formerly known as The Bank of New York Trust Company, N.A.) (as successor to The Bank of New York), as trustee (the “Trustee”) (the “Original Indenture”), as supplemented by a twenty-eighth supplemental indenture, dated as of March 13, 2024, by and between the Company and the Trustee relating to the 2031 Senior Notes (the “Twenty-Eighth Supplemental Indenture””
HUMANA INC entered into Underwriting Agreement with Citigroup Global Markets Inc., Goldman Sachs & Co. LLC, Morgan Stanley & Co. LLC, PNC Capital Markets LLC and Wells Fargo Securities, LLC valued at $1,250 million aggregate principal amount of its 5.375% Senior Notes due 2031 and $1,000 million agg (effective 2024-03-11).
“On March 11, 2024, Humana Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Citigroup Global Markets Inc., Goldman Sachs & Co. LLC, Morgan Stanley & Co. LLC, PNC Capital Markets LLC and Wells Fargo Securities, LLC , as representatives of the several underwriters (together, the “Underwriters”), pursuant to which the Company agreed to issue and sell to the Underwriters $1,250 million aggregate principal amount of its 5.375% Senior Notes due 2031 (the “2031 Senior Notes”) and $1,000 million aggregate principal amount of its 5.750% Senior Notes due 2054 (the “2054 Senior Notes” and, together with the 2031 Senior Notes, the “Senior Notes”), in accordance with the terms and conditions set forth in the Underwriting Agreement.”
HUMANA INC reported the year ending December 31, 2024 results: EPS approximately $14.87. Guidance initiated.
“Humana provided its initial GAAP and Adjusted EPS guidance for the year ending December 31, 2024 (FY 2024) as detailed below. GAAP and Adjusted EPS results for FY 2023 are also shown for comparison. Diluted earnings per common share FY 2024 Guidance (c) FY 2023 (a) GAAP approximately $14.87 $20.00”
HUMANA INC reported the year ended December 31, 2023 results: EPS $20.00.
“Humana Reports Fourth Quarter 2023 Financial Results; Provides Initial Full Year 2024 Financial Guidance • Reports 4Q23 loss per share of $4.42 on a GAAP basis, Adjusted loss per share of $0.11; reports FY 2023 earnings per share (EPS) of $20.00 on a GAAP basis, $26.09 on an Adjusted basis”
HUMANA INC reported the quarter ended December 31, 2023 results: EPS ($4.42).
“Humana Reports Fourth Quarter 2023 Financial Results; Provides Initial Full Year 2024 Financial Guidance • Reports 4Q23 loss per share of $4.42 on a GAAP basis, Adjusted loss per share of $0.11; reports FY 2023 earnings per share (EPS) of $20.00 on a GAAP basis, $26.09 on an Adjusted basis”
HUMANA INC: Removed requirement to maintain an Executive Committee and disbanded the committee (effective 2023-12-07).
“The Restated By-laws amend Article III to remove the requirement that the Board maintain an Executive Committee. The Board simultaneously disbanded its Executive Committee.”
HUMANA INC incurred senior notes of $500 million aggregate principal amount of its 5.750% Senior Notes due 2028 and $850 million aggregate principal amount with The Bank of New York Mellon Trust Company, N.A. at 5.750% per annum for the 2028 Senior Notes and 5.950% per annum for the 2034 Sen maturing December 1, 2028 for the 2028 Senior Notes and March 15, 2034 for the 2034 Senior Notes.
“On November 9, 2023, Humana Inc. (the “Company”) completed a public offering of $500 million aggregate principal amount of its 5.750% Senior Notes due 2028 (the “2028 Senior Notes”) and $850 million aggregate principal amount of its 5.950% Senior Notes due 2034 (the “2034 Senior Notes” and, together with the 2028 Senior Notes, the “Senior Notes”).”
HUMANA INC entered into Twenty-Sixth Supplemental Indenture and Twenty-Seventh Supplemental Indenture with The Bank of New York Mellon Trust Company, N.A. valued at $500 million principal of 5.750% Senior Notes due 2028 and $850 million principal of 5.950% Senior N (effective 2023-11-09).
“On November 9, 2023, Humana Inc. (the “Company”) completed a public offering of $500 million aggregate principal amount of its 5.750% Senior Notes due 2028 (the “2028 Senior Notes”) and $850 million aggregate principal amount of its 5.950% Senior Notes due 2034 (the “2034 Senior Notes” and, together with the 2028 Senior Notes, the “Senior Notes”).”
HUMANA INC entered into Underwriting Agreement with Barclays Capital Inc., BofA Securities, Inc., Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC and Truist Securities, Inc., as representatives of the several underwriters valued at $500 million aggregate principal amount of its 5.750% Senior Notes due 2028 and $850 million aggrega (effective 2023-11-02).
“On November 2, 2023, Humana Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Barclays Capital Inc., BofA Securities, Inc., Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC and Truist Securities, Inc. , as representatives of the several underwriters (together, the “Underwriters”), pursuant to which the Company agreed to issue and sell to the Underwriters $500 million aggregate principal amount of its 5.750% Senior Notes due 2028 (the “2028 Senior Notes”) and $850 million aggregate principal amount of its 5.950% Senior Notes due 2034”
HUMANA INC reported the quarter ended September 30, 2023 (3Q23) results: revenue $26,423, EPS $6.71.
“by Humana on February 23, 2023 . Humana Inc. Summary of Results ($ in millions, except per share amounts) 3Q23 (a) 3Q22 (a) YTD 2023 (a) YTD 2022 (a) CONSOLIDATED Revenues $26,423 $22,799 $79,912 $70,431 Revenues - Adjusted (non-GAAP) $25,526 $21,600 $76,911 $67,001 Pretax results $1,098 $1,297 $3,974 $3,639 Pretax results - Adjusted (non-GAAP) $1,268”
Bruce D. Broussard departed as Chief Executive Officer at HUMANA INC.
“As part of a multi-year succession plan, the Company expects that Mr. Broussard will step down as Chief Executive Officer in the latter half of 2024 and that Mr. Rechtin would become President and Chief Executive Officer at that time.”
James A. Rechtin was appointed as President and Chief Operating Officer at HUMANA INC.
“On October 11, 2023, Humana Inc. (the “Company”) announced the election of James A. Rechtin (“Mr. Rechtin”), age 52, to serve as the Company’s President and Chief Operating Officer, effective as of the later of (x) January 8, 2024, or (y) commencement of his employment with the Company.”
HUMANA INC reported the quarter ended June 30, 2023 (2Q23) results: revenue $26,747, EPS $7.66.
“by Humana on February 23, 2023 . 2 Humana Inc. Summary of Results ($ in millions, except per share amounts) 2Q23 (a) 2Q22 (b) YTD 2023 (c) YTD 2022 (d) CONSOLIDATED Revenues $26,747 $23,662 $53,489 $47,632 Revenues - Adjusted (non-GAAP) $25,733 $22,540 $51,385 $45,402 Pretax results $1,262 $1,122 $2,876 $2,342 Pretax results - Adjusted (non-GAAP) $1,470”
HUMANA INC incurred revolving credit of $1.5 billion with JPMorgan Chase Bank, N.A. as Agent at Term SOFR or the base rate plus a spread maturing 364-day.
“(the “Company”) entered into two separate revolving credit facilities: (i) a five-year $2.5 billion unsecured revolving credit agreement with the several banks and other financial institutions from time to time parties thereto, JPMorgan Chase Bank, N.A. as Agent, Bank of America, N.A. as the Syndication Agent, Citibank, N.A., Goldman Sachs Bank USA, PNC Capital Markets LLC, U.S.”
HUMANA INC incurred revolving credit of $2.5 billion with JPMorgan Chase Bank, N.A. as Agent at Term SOFR or the base rate plus a spread maturing five years.
“(the “Company”) entered into two separate revolving credit facilities: (i) a five-year $2.5 billion unsecured revolving credit agreement with the several banks and other financial institutions from time to time parties thereto, JPMorgan Chase Bank, N.A. as Agent, Bank of America, N.A. as the Syndication Agent, Citibank, N.A., Goldman Sachs Bank USA, PNC Capital Markets LLC, U.S.”
HUMANA INC terminated Previous Credit Agreement with various banks and financial institutions valued at $2.5 billion unsecured revolving credit agreement dated as of June 4, 2021, terminated and replaced (effective 2023-06-02).
“Item 1.02 Termination of a Material Definitive Agreement. The 5-Year Credit Agreement replaces the Previous Credit Agreement in its entirety.”
HUMANA INC entered into 364-Day Credit Agreement with JPMorgan Chase Bank, N.A., Bank of America, N.A., Citibank, N.A., Goldman Sachs Bank USA, PNC Capital Markets LLC, U.S. Bank, National Association, Wells Fargo Securities, LLC valued at $1.5 billion unsecured revolving credit facility (effective 2023-06-02).
“On June 2, 2023, Humana Inc. (the “Company”) entered into two separate revolving credit facilities: (i) a five-year $2.5 billion unsecured revolving credit agreement with the several banks and other financial institutions from time to time parties thereto, JPMorgan Chase Bank, N.A. as Agent, Bank of America, N.A. as the Syndication Agent, Citibank, N.A., Goldman Sachs Bank USA, PNC Capital Markets LLC, U.S. Bank, National Association and Wells Fargo Securities, LLC, as Documentation Agents, and JPMorgan Chase Bank, N.A., BofA Securities, Inc., Citibank, N.A., Goldman Sachs Bank USA, PNC Capital Markets LLC, U.S. Bank, National Association and Wells Fargo Securities, LLC, as Joint-Lead Arrangers and Joint Bookrunners (the “5-Year Credit Agreement”), which amended and restated the Company’s five-year, $2.5 billion unsecured revolving credit agreement dated as of June 4, 2021 (as amended, the “Previous Credit Agreement”), and (ii) a 364-day $1.5 billion unsecured revolving credit agreemen”
HUMANA INC entered into 5-Year Credit Agreement with JPMorgan Chase Bank, N.A., Bank of America, N.A., Citibank, N.A., Goldman Sachs Bank USA, PNC Capital Markets LLC, U.S. Bank, National Association, Wells Fargo Securities, LLC valued at $2.5 billion unsecured revolving credit facility (effective 2023-06-02).
“On June 2, 2023, Humana Inc. (the “Company”) entered into two separate revolving credit facilities: (i) a five-year $2.5 billion unsecured revolving credit agreement with the several banks and other financial institutions from time to time parties thereto, JPMorgan Chase Bank, N.A. as Agent, Bank of America, N.A. as the Syndication Agent, Citibank, N.A., Goldman Sachs Bank USA, PNC Capital Markets LLC, U.S. Bank, National Association and Wells Fargo Securities, LLC, as Documentation Agents, and JPMorgan Chase Bank, N.A., BofA Securities, Inc., Citibank, N.A., Goldman Sachs Bank USA, PNC Capital Markets LLC, U.S. Bank, National Association and Wells Fargo Securities, LLC, as Joint-Lead Arrangers and Joint Bookrunners (the “5-Year Credit Agreement”), which amended and restated the Company’s five-year, $2.5 billion unsecured revolving credit agreement dated as of June 4, 2021 (as amended, the “Previous Credit Agreement”)”
HUMANA INC reported FY 2023 results: EPS at least $27.88. Guidance raised.
“Humana raised its GAAP and Adjusted EPS guidance for the year ending December 31, 2023 (FY 2023). The company now expects FY 2023 GAAP to be 'at least $27.88', while Adjusted EPS is expected to be 'at least $28.25'.”
HUMANA INC reported the quarter ended March 31, 2023 results: revenue $26,742, EPS $9.87.
“CONSOLIDATED Revenues $26,742 $23,970 Revenues - Adjusted (non-GAAP) $25,652 $22,862 Pretax results $1,614 $1,220 Pretax results - Adjusted (non-GAAP) $1,552 $1,307 EPS $9.87 $7.29”
HUMANA INC shareholders approved Board proposal regarding advisory vote with respect to the frequency of future stockholder votes on executive compensation at the 2023-04-20 meeting.
“Proposal #4 Every Year Every Two Years Every Three Years Abstain Board proposal regarding advisory vote with respect to the frequency of future stockholder votes on executive compensation 107,067,594 108,274 2,119,797 101,926”
HUMANA INC shareholders approved Board proposal regarding advisory approval of the Company’s executive compensation at the 2023-04-20 meeting.
“Proposal #3 For Against Abstained Broker Non-Votes Board proposal regarding advisory approval of the Company’s executive compensation 99,607,320 9,492,897 297,374 4,607,399”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.